Abeona Therapeutics Insider Faith L. Charles Buys $34.3K of Stock
Faith L. Charles bought 15,000 shares of Abeona Therapeutics Inc. at $2.29 a share, worth $34.3K in total on Nov 13, 2026. Shares held after the trade: 191,407 (+8.5%).
Abeona Therapeutics reported a decrease in cash and short-term investments to $134.9 million as of September 30, 2026, compared to $191.4 million at year-end 2025. The company is focused on the commercialization of ZEVASKYN and the development of ABO-801, while noting a private placement transaction announced on November 9, 2026.
Abeona Therapeutics reported Q3 2026 financial results, highlighted by $13.5 million in net ZEVASKYN revenue, an 18% sequential increase. The company completed six ZEVASKYN treatments during the quarter and expanded its qualified treatment center network to eight sites. Additionally, Abeona announced the acquisition of a Phase 3-ready asset, APT-1011, for eosinophilic esophagitis and a $30 million PIPE financing.
Term
Q3 2026
“Maximizing the opportunity for ZEVASKYN remains our number one priority. During the third quarter, we continued to build the commercial foundation for ZEVASKYN, with expansion of our QTC network and more centers gaining firsthand treatment experience.”
Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics
“The acquisition of APT-1011 represents an important step in building Abeona into a diversified commercial-stage company, adding a uniquely differentiated late-stage orphan-drug asset with substantial commercial potential in a rapidly growing disease with high unmet need.”
Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics
Abeona Therapeutics Signs $20M M&A Deal with Ellodi Pharmaceuticals, L.P.
Abeona Therapeutics acquired substantially all assets related to APT-1011 (now ABO-801), a Phase 3-ready candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals. The deal was structured with $20 million in upfront equity consideration (4,494,383 shares) and no upfront cash, with Ellodi eligible for $30 million upon FDA approval and up to $30 million in sales milestones plus royalties.
Value
$20M
Counterparty
Ellodi Pharmaceuticals, L.P.
“The acquisition of ABO-801 is an important step in building Abeona into a diversified commercial-stage company with multiple opportunities for value inflection, adding an asset with substantial revenue potential in a rapidly growing disease.”
Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics
Madhav Vasanthavada, Chief Commercial Officer, sold 4,902 shares of Abeona Therapeutics Inc. at $5.16 a share, worth $25.3K in total on Sep 29, 2026. Shares held after the trade: 285,721 (-1.7%).
Abeona Therapeutics SVP, CLO Brendan M. O'Malley Sells $34.7K of Stock
Brendan M. O'Malley, SVP, CLO, sold 6,727 shares of Abeona Therapeutics Inc. at $5.16 a share, worth $34.7K in total on Sep 29, 2026. Shares held after the trade: 421,226 (-1.6%).
Abeona Therapeutics CFO Joseph Walter Vazzano Sells $47.4K of Stock
Joseph Walter Vazzano, CFO, sold 9,191 shares of Abeona Therapeutics Inc. at $5.16 a share, worth $47.4K in total on Sep 29, 2026. Shares held after the trade: 482,888 (-1.9%).
Abeona Therapeutics CEO Vishwas Seshadri Sells $101K of Stock
Vishwas Seshadri, CEO, sold 19,608 shares of Abeona Therapeutics Inc. at $5.16 a share, worth $101K in total on Sep 29, 2026. Shares held after the trade: 1,286,500 (-1.5%).
Abeona Therapeutics Inc. filed an updated investor presentation for its appearance at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The presentation provides a strategic update on the company's clinical pipeline and corporate milestones to the investment community.